BS_6VPKXXMR
high-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- high-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- high-grade glioma
- overall_survival_months
- 27.726675427069644
- age_years
- 18.016
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.615
- MYC_TARGETS_V1+0.496
- G2M_CHECKPOINT+0.487
- MTORC1_SIGNALING+0.367
- OXIDATIVE_PHOSPHORYLATION+0.357
- MYC_TARGETS_V2+0.352
- DNA_REPAIR+0.310
- UNFOLDED_PROTEIN_RESPONSE+0.308
- PROTEIN_SECRETION+0.259
- SPERMATOGENESIS+0.179
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.424
- APICAL_SURFACE-0.371
- ESTROGEN_RESPONSE_EARLY-0.347
- MYOGENESIS-0.322
- ESTROGEN_RESPONSE_LATE-0.308
- P53_PATHWAY-0.287
- IL2_STAT5_SIGNALING-0.282
- UV_RESPONSE_DN-0.280
- KRAS_SIGNALING_DN-0.273
- ALLOGRAFT_REJECTION-0.271
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_052PZFMK | high-grade glioma | — | 0.886 |
| 2 | BS_YBJBSRHV | Embryonal tumors | — | 0.882 |
| 3 | 5712498e-366d-4b30-b131-ae7209d59842 | — | — | 0.860 |
| 4 | 45a758dc-af09-48d3-8cd2-15232593f385 | — | — | 0.856 |
| 5 | BS_A0DYVX9J | high-grade glioma | — | 0.849 |
| 6 | SRR12475130 | — | — | 0.849 |
| 7 | c6e243ee-b2d9-408e-ac05-ccbcffa805ab | — | — | 0.846 |
| 8 | SRR4195680 | — | — | 0.844 |
| 9 | BS_G23JJAZY | EPN | Supratentorial EPN | 0.839 |
| 10 | MNG1178 | — | — | 0.839 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.615 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.496 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.487 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.367 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.357 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.352 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.310 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.308 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.259 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.179 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.114 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.112 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.095 | Inavolisib | — uncovered |
| COAGULATION | 0.089 | Binimetinib | — uncovered |
| GLYCOLYSIS | 0.088 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.087 | Inavolisib | — uncovered |
| PEROXISOME | 0.074 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.037 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.027 | Inavolisib | — uncovered |
| HYPOXIA | 0.026 | Idelalisib | — uncovered |